Brought to you by 
Lux Biosciences gets eye disease candidate from Isotechnika; terminated
11 Jun 2021
Executive Summary
Canadian biotech Isotechnika (autoimmune diseases and diagnostics) licensed ophthalmic disease company Lux Biosciences exclusive worldwide development and marketing rights to ISA247 for the treatment and prevention of all eye disorders, expanding the candidate's use beyond immunosuppression.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lux Biosciences gets eye disease candidate from Isotechnika; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice